Hexarelin dosage: Frequently asked questions

Increase the dose to 150 mcg per injection and verify that administration occurs in a true fasted state (no food intake for at least three hours prior). Individual variability in pituitary sensitivity means some models require doses at the higher end of the effective range to cross the GH secretion threshold. Research models with higher baseline growth hormone levels or prior exposure to growth hormone secretagogues often show attenuated responses at lower doses. If 150 mcg per injection still produces no measurable shift in body composition after four weeks, consider peptide purity. Subtherapeutic batches do exist, and amino acid sequencing errors reduce receptor binding affinity.

Administer the missed dose as soon as you realize it, then resume the regular schedule. Do not double-dose to compensate. Hexarelin's short half-life means a missed dose results in a missed GH pulse, but doubling the next dose doesn't recover that pulse. It just oversaturates receptors without additional benefit and increases desensitization risk.

Structure your protocol as 4–6 week cycles with mandatory 2–3 week washout periods between cycles. Research from the European Journal of Endocrinology demonstrates that ghrelin receptor density recovers to 85–95% of baseline within 14–21 days of cessation, allowing subsequent cycles to produce GH responses comparable to the initial cycle. Continuous administration beyond eight weeks without breaks results in progressive GH response degradation. By week 10–12, many subjects show GH elevation of only 300–500% above baseline despite unchanged dosing, compared to 1,200–1,600% in week one.

No. CD36-mediated cardioprotection depends on sustained receptor occupancy, not peak concentration. Missing a dose creates a 12-hour gap in signalling, but doubling the next administration (to 200–400 mcg) pushes you into supraphysiological GH territory without recovering the lost cardiac coverage. Resume at your standard 100 mcg dose and maintain the twice-daily schedule. Consistency over weeks matters more than any single missed injection.

Use the actual stated amount on the vial label, not the nominal amount. If your vial is labelled 4.8mg and you add 2mL bacteriostatic water, your concentration is 4800mcg ÷ 2mL = 2400mcg/mL, not 2500mcg/mL. That 4% difference compounds across multiple doses. Over a 30-dose protocol, you'd underdose by 1.2 full injections if you used the wrong concentration. Peptide fill amounts vary by ±5–10% during lyophilisation; treat the vial label as ground truth and recalculate every time you reconstitute a new vial.

Calculate the exact volume first: 225mcg ÷ 2500mcg/mL = 0.09mL = 9 insulin syringe units. Insulin syringes graduate in 1-unit increments (0.01mL), so you can measure 9 units precisely without rounding. The decimal doesn't require approximation. It translates directly to a marked gradation on the syringe. If your calculation yields something like 0.087mL (8.7 units), round to the nearest unit. In this case, 9 units. The ±0.3mcg dosing variance from rounding 0.01mL at 2500mcg/mL concentration is clinically negligible for research purposes.

Recalculate your concentration immediately: 5000mcg ÷ 2.3mL = 2174mcg/mL instead of 2500mcg/mL. To deliver 250mcg, you now need 250mcg ÷ 2174mcg/mL = 0.115mL (11.5 units) instead of 0.1mL. The peptide isn't ruined. It's just at a different concentration. Mark the vial clearly with the actual volume added and the recalculated concentration. Do not try to 'correct' the volume by withdrawing bacteriostatic water. Removing liquid from a sealed vial creates negative pressure that can denature the peptide during subsequent needle insertions.

Convert the weight-based dose to an absolute microgram amount first. If the protocol calls for 2mcg Hexarelin per kg bodyweight and your test subject weighs 75kg, the target dose is 2mcg/kg × 75kg = 150mcg total. Then apply the standard formula: 150mcg ÷ 2500mcg/mL = 0.06mL injection volume. Weight-based dosing requires recalculating the absolute dose for each subject before converting to injection volume. Never calculate mL/kg directly, as that skips the critical concentration step and yields incorrect results.

Hexarelin dosing in research contexts typically uses fixed microgram amounts (100mcg, 200mcg) rather than weight-adjusted dosing, unlike many other research compounds. Published trials administer identical absolute doses across subjects regardless of body weight. A 60kg and 90kg subject both receive 200mcg. If your specific protocol requires weight-adjusted dosing (e.g., 2mcg/kg), calculate each subject's dose individually, then determine the injection volume using the concentration formula. For a 75kg subject at 2mcg/kg: 75 × 2 = 150mcg target dose; at 2.5mg/mL concentration, draw 6 units. Create a dosing table listing each subject ID, body weight, calculated dose, and corresponding syringe volume before beginning administration.

Recalculate concentration immediately using actual volume added, then adjust drawn volume per dose accordingly. If you intended 2mL but added 2.5mL, concentration drops from 2.5mg/mL to 2mg/mL (5mg ÷ 2.5mL). Your 200mcg dose now requires 0.1mL (10 units) instead of 8 units. Mark the vial with the actual concentration and corresponding dose volume to prevent mid-protocol confusion. The peptide remains stable and usable; only the math changes. Do not attempt to compensate by drawing less water from the next vial. Maintain consistency within each reconstituted batch.

Round to the nearest whole unit and document the effective dose delivered. Standard U-100 insulin syringes mark single-unit increments (0.01mL each). Fractional units (e.g., 6.5 units) cannot be measured reliably without specialized syringes. For a calculated dose of 180mcg requiring 7.2 units at 2.5mg/mL concentration, draw 7 units (175mcg actual) and maintain that rounded dose across all administrations for consistency. If fractional precision is essential for the research protocol, reconstitute at a volume that produces whole-unit doses: 2.22mL reconstitution yields 2.25mg/mL, where 180mcg = exactly 8 units.

Discard the vial immediately. Cloudiness or visible particles indicate protein aggregation or contamination, both of which render the peptide unusable for research. Properly reconstituted Hexarelin should be clear and colorless. Aggregation occurs when bacteriostatic water is added too forcefully (disrupting peptide structure), when the lyophilised powder was exposed to temperature excursions before reconstitution, or when the water itself is contaminated. Real Peptides' bacteriostatic water contains 0.9% benzyl alcohol as preservative, which maintains sterility across multiple draws. Always use pharmaceutical-grade bacteriostatic water rather than sterile water for multi-dose vials. Reconstitute a fresh vial with gentle technique: inject water slowly down the vial wall rather than directly onto the lyophilised cake, then swirl gently without shaking.

Do not double the next dose to compensate. Hexarelin's GH pulse is dose-dependent up to receptor saturation (150–200mcg), but administering a doubled dose after a missed injection doesn't recover the lost anabolic window. It increases the risk of transient cortisol elevation and water retention without additional muscle protein synthesis benefit. Resume the regular schedule at the next planned administration time and maintain consistent timing going forward.

This is expected receptor desensitization, not product degradation. GHS-R1a receptors downregulate with continuous agonist stimulation. Hexarelin's GH-releasing potency declines 30–50% by week 4 in continuous daily protocols. Implement a 2-week washout period to allow receptor repopulation, then resume with a 5-on-2-off cycling protocol. Escalating the dose to compensate for desensitization accelerates receptor downregulation further and increases side effect incidence without recovering initial efficacy.

Hexarelin stacks synergistically with GHRH analogues like CJC-1295 or modified GRF(1-29) because they act on different receptors. Hexarelin stimulates GHS-R1a (ghrelin pathway) while GHRH analogues activate GHRH receptors on somatotrophs. This dual-pathway activation produces higher GH peaks than either peptide alone, with studies showing 150% greater GH output when hexarelin and GHRH are co-administered. Do not combine hexarelin with other ghrelin mimetics (GHRP-2, GHRP-6, ipamorelin) during active weeks. They compete for the same receptors and accelerate desensitization without increasing GH output.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed, then resume your normal schedule the next day. If more than 12 hours have elapsed, skip the missed dose and continue with the next scheduled administration. Do not double-dose. The cardioprotective signaling from Hexarelin builds cumulatively over days to weeks; missing a single dose in a 28-day protocol reduces overall efficacy minimally (estimated 2–4% reduction in endpoint measures based on daily dosing models).

Partially, but not optimally. Standard GH protocols use 100–200 mcg per dose (often 1–2 mg/kg for a 70 kg person), which far exceeds the 2–4 mcg/kg range where cardiac signaling is most efficient. You'll activate CD36 receptors, but the disproportionate GH surge introduces cortisol elevation, insulin resistance risk, and potential receptor desensitization with chronic use. If cardiac protection is the goal, a separate lower-dose administration targeting CD36 pathways delivers better outcomes without systemic endocrine disruption.

Discard it immediately. Cloudiness indicates bacterial contamination or peptide aggregation. Both destroy bioactivity. Hexarelin reconstituted with bacteriostatic water maintains stability for 28 days when refrigerated at 2–8°C, but only if sterile technique was used during mixing. Store unreconstituted lyophilized powder at −20°C; once mixed, never freeze. Freeze-thaw cycles denature the peptide structure irreversibly.

Skip the dose or wait 2+ hours. Elevated insulin from protein ingestion (especially fast-digesting sources like whey) suppresses GH release through direct inhibition of ghrelin receptor signaling. Even protein meals without carbohydrates blunt hexarelin's efficacy by 25–35%. Administering hexarelin in a fasted state (minimum 2 hours post-meal) preserves receptor sensitivity and maximizes GH pulse amplitude. If meal timing is unavoidable, prioritize low-glycemic, fat-dominant meals over high-protein or high-carb options.

Hexarelin is a ghrelin receptor agonist. Appetite stimulation is an on-target effect, not a side effect. The orexigenic response peaks 60–90 minutes post-injection and resolves within 3–4 hours. Timing doses immediately before scheduled meals or 90 minutes pre-sleep minimizes unscheduled eating. If appetite interference disrupts caloric deficit targets, reduce individual dose to 50–75mcg while increasing frequency to maintain total daily exposure.